//

Chiron Corp

Posted Mon, 09/14/2009 - 12:26 by Zefu

Chiron Corp

4560 Horton Street
Emeryville, CA 94608
USA
Phone: (510) 655-8730
Fax: (510) 655-9910
Web Site: http://www.chiron.com/

A. Company Profile

Chiron (NASDAQ:CHIR) is one of the world's leading biotech companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology at Chiron.

B. Products

Product Pipelines
Product Indication Clinical Status
Angiozyme Various tumors Phase I-II
Chir258 Various tumors Phase I
Proleukin Melanoma Market
Proleukin plus rituximab Non-Hodgekin's lymphoma Phase II
Tezacitabine Colorectal and esophagogastric cancers Phase II

1. Angiozyme

Angiozyme is a synthetic ribozyme that specifically inhibits vascular endothelial growth factor, a key component in the angiogenesis pathway. Since angiogenesis plays a significant role in the growth and metastasis of several important human tumors such as lung cancer, breast cancer, melanoma and renal cell carcinoma, Angiozyme has the potential to benefit a large group of patients.

2. Chir258

Chir258 is a small molecule anti-cancer compound.

3. Proleukin

Proleukin (aldesleukin, interleukin-2) has a demonstrated record in the treatment of metastatic melanoma and metastatic renal cell cancer and is being tested in combination therapy with monoclonal antibodies for the treatment of non-Hodgkin's lymphoma.

4. Tezacitabine

Tezacitabine (FMdC) interrupts DNA replication and is a nucleoside analogue, to treat cancer. Nucleoside analogues are a class of drugs that affect DNA synthesis.